Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | case report

Sorafenib in thyroid cancer—a retrospective case series

verfasst von: Gabriele Gamerith, MD, Andreas Pircher, MD, Arno Amann, MD, Katharina Cima, MD, Klaus Gasser, MD, Markus Lenzhofer, MD, Peter Lind, MD, Evelyne Bareck, MD, Ewald Wöll, MD, Wolfgang Hilbe, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

In recent times, the treatment of advanced disease stages of thyroid cancer (TC) followed the strategy of targeted therapy with encouraging results. Thus, eight patients with metastasized thyroid carcinomas, who had multiple lines of prior interventions, were treated with sorafenib and have now been retrospectively evaluated. This retrospective evaluation included four patients with classified medullar carcinoma, two follicular, one papillary and one anaplastic, respectively. Within this population a clinical benefit rate of more than 70 % in daily routine, including a 29 % partial response rate could be determined, which correlates with the findings of recently published clinical trials with multi-kinase inhibitors. Furthermore, in all patients the observed toxicities were manageable after dose reductions. In conclusion, these data support a potential value of sorafenib in treatment of this rare disease.
Vorheriger Artikel Follow-up care for head and neck cancer patients
Literatur
1.
Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2007;8:83–95.CrossRef
2.
Pearce EN, Braverman LE. Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab. 2004;89:3710–2.PubMedCrossRef
3.
Shimaoka KSD, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–60.PubMedCrossRef
4.
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645–55.PubMed
5.
Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III Trial. J Clin Oncol. 2012;30:134–41.PubMedCrossRef
6.
Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib Is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708–13.PubMedCrossRef
7.
Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794–801.PubMedCrossRef
8.
Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.PubMedCrossRef
9.
Kloos RT, Ringel MD, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–84.PubMedCrossRef
10.
Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323–30.PubMedCrossRef
11.
Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161:923–31.PubMedCrossRef
12.
Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–44.PubMedCrossRef
13.
Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95:2588–95.PubMedCrossRef
14.
Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165:315–22.PubMedCrossRef
15.
Liebner DA, Shah MH. Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2011;2:173–95.CrossRef
16.
Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JWR, Smit JWA. New treatment modalities in advanced thyroid cancer. Ann Oncol. 2012;23:10–8.PubMedCrossRef
Metadaten
Titel
Sorafenib in thyroid cancer—a retrospective case series
verfasst von
Gabriele Gamerith, MD
Andreas Pircher, MD
Arno Amann, MD
Katharina Cima, MD
Klaus Gasser, MD
Markus Lenzhofer, MD
Peter Lind, MD
Evelyne Bareck, MD
Ewald Wöll, MD
Wolfgang Hilbe, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0033-0

Weitere Artikel der Ausgabe 3/2012

Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology

  • short review

Follow-up care for head and neck cancer patients

  • short review

Clinically useful biomarkers in neurooncology

  • short review

The End-of-Life in patients with glioma and their families

  • short review

ASH 2011: “Real generosity toward the future lies in giving all to the present”

  • editorial

Drug therapy for recurrent, progressive, atypical, and malignant meningiomas

  • short review